Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2024-05-07 Earnings Release
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
Earnings Release Classification · 100% confidence The document is titled 'Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024' and explicitly mentions 'Quarter Results' as a keyword. It provides key financial metrics (revenue, EBIT, earnings per share) for the first quarter of 2024 and includes an 'Outlook' for the full 2024 financial year. This structure—a brief announcement highlighting key figures for a recent period, distinct from a comprehensive annual report (10-K) or a detailed interim report (IR)—is characteristic of an Earnings Release (ER). It is an initial announcement of periodical financial results. Q1 2024
2024-05-07 English
Q1 statement / Q1 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the period ending 31 March 2024. It contains detailed financial performance metrics, including consolidated statements of income, financial position, and cash flow, as well as management's analysis of business performance, research and development, and financial position. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-07 English
Annual financial report 2023
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2023' and contains comprehensive financial statements, including the consolidated statement of income, financial position, cash flows, and changes in equity, as well as a group management report and notes to the financial statements. It covers the full fiscal year 2023 and provides detailed performance metrics, meeting the criteria for an Annual Report (10-K). FY 2023
2024-04-29 English
Audit Report / Information 2023
Audit Report / Information Classification · 95% confidence The document text explicitly states "BIOTEST GROUP FY 2023 Results, March 28, 2024" and contains extensive details about the company's performance across various product lines (Immunoglobulins, Haematology, Intensive Care), R&D pipeline updates (Fibrinogen trials, Trimodulin trials), operational metrics (Plasma Collection Centres), and strategic collaborations (Grifols). The content structure, including leadership teams, operational models, and detailed financial/product reviews for a full fiscal year (FY 2023), strongly indicates a comprehensive annual report or a document summarizing annual results. Since the document is very long (over 21,000 characters) and provides deep operational and financial context, it is classified as an Annual Report (10-K) or a document closely related to it, such as an Annual Report/Results Presentation. Given the context of financial reporting, and the depth of the FY 2023 review, 10-K is the most appropriate regulatory equivalent for a comprehensive annual review, although it might technically be an Annual Report presentation (AR). However, the depth suggests the core content of an annual filing. I will select 10-K as the primary classification for a full-year results review of this magnitude, as it covers all aspects typically found in a 10-K. FY 2023
2024-04-25 English
Biotest AG opens 12th plasma collection centre in Germany
Regulatory Filings Classification · 100% confidence The document is titled 'News Details' and begins with a press release format announcing a corporate event: 'Biotest AG opens 12th plasma collection centre in Germany'. It is dated April 19, 2024, and explicitly states it is a 'PRESS RELEASE' disseminated via 'EQS-News'. This type of announcement, which details operational updates, expansion, or non-financial corporate news, does not fit the specific financial reporting categories (10-K, IR, ER, MRQ) or specific corporate actions (DIV, CAP, DIRS). Since it is a general corporate news release distributed through a regulatory news service (EQS), and it is not a formal financial report or a specific governance/shareholder document, the most appropriate classification is the general regulatory announcement/miscellaneous category, RNS.
2024-04-19 English
Biotest Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 07.05.2024 in Frankfurt am Main mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is explicitly titled "Bekanntmachung der Einberufung zur Hauptversammlung am 07.05.2024" (Announcement of the Convocation to the Annual General Meeting on 07.05.2024) and contains a detailed "Tagesordnung" (Agenda) for the upcoming meeting. Key agenda items include the approval of the 2023 financial statements, dividend proposals, discharge of board members, and proposals regarding the company's articles of association (Satzung), including provisions for virtual AGMs and authorized capital. The document is an official invitation to shareholders to attend the AGM. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, and specifically, the convocation notice itself falls under this category or related proxy/meeting materials. Since it is the formal invitation/convocation notice for the AGM, AGM-R is the most precise fit. It is not a DEF 14A (which is specifically about remuneration reports, although remuneration is discussed here as an agenda item) nor a 10-K (which is the full annual report itself, which is only being presented for approval).
2024-03-28 German

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.